SAE1 and UBA2 form a heterodimer that functions as a SUMO-activating enzyme for the sumoylation of proteins to regulate protein structures and intracellular localization (1). The SAE1/SAE2 dimer functions in SUMO1 activation in a manner analogous to the single E1 ubiquitin-activating enzymes (2). The SAE2 inactivation may be a therapeutic strategy in MYC-driven cancers (3).
SAE1: UBLE1A; SUA1; HSPC140; AOS1; FLJ3091
UBA2: SAE2; UBLE1B; SAE2; ARX; HRIHFB2115
1. Okuma, T. et.al: In vitro SUMO-1 modification requires two enzymatic steps, E1 and E2. Biochem. Biophys. Res. Commun. 254: 693-698, 1999.
2. Desterro, J. et. al: Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J. Biol. Chem. 274: 10618-10624, 1999.
3. Kessler, J. D. et.al: A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335: 348-353, 2012.
Sample Activity Plot. For specific information on a given lot, see related technical data sheet.
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability, and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
SAE1 ~39 kDa and UBA2 ~115 kDa
There are no related publications available for this product.
Cancer, Cell Cycle, Neurobiology